RU2008150250A - Способ лечения рака - Google Patents
Способ лечения рака Download PDFInfo
- Publication number
- RU2008150250A RU2008150250A RU2008150250/14A RU2008150250A RU2008150250A RU 2008150250 A RU2008150250 A RU 2008150250A RU 2008150250/14 A RU2008150250/14 A RU 2008150250/14A RU 2008150250 A RU2008150250 A RU 2008150250A RU 2008150250 A RU2008150250 A RU 2008150250A
- Authority
- RU
- Russia
- Prior art keywords
- mammal
- administering
- formula
- therapeutically effective
- effective amount
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 241000124008 Mammalia Species 0.000 claims abstract 28
- 150000001875 compounds Chemical class 0.000 claims abstract 16
- 206010006187 Breast cancer Diseases 0.000 claims abstract 8
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 8
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims abstract 6
- 229960000303 topotecan Drugs 0.000 claims abstract 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract 4
- 201000005202 lung cancer Diseases 0.000 claims abstract 4
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 4
- 206010009944 Colon cancer Diseases 0.000 claims abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims abstract 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims abstract 2
- 229960003668 docetaxel Drugs 0.000 claims abstract 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960003881 letrozole Drugs 0.000 claims abstract 2
- 229960000575 trastuzumab Drugs 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1. Способ лечения рака молочной железы у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств ! 1) соединения формулы (I") ! ! 2) трастузумаба. ! 2. Способ лечения рака молочной железы у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств ! 1) соединения формулы (I") ! ! 2) летрозола. ! 3. Способ лечения рака молочной железы у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств ! 1) соединения формулы (I") ! ! 2) топотекана. ! 4. Способ лечения рака легких у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств ! 1) соединения формулы (I") ! ! 2) доцетаксела. ! 5. Способ лечения рака легких у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств ! 1) соединения формулы (I") ! ! 2) топотекана. ! 6. Способ лечения колоректального рака у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств ! 1) соединения формулы (I") ! ! 2) топотекана. ! 7. Способ лечения рака молочной железы у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств ! 1) соединения формулы (I") ! ! 2) соединения с антиэстрогенной активностью.
Claims (7)
1. Способ лечения рака молочной железы у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств
1) соединения формулы (I")
2) трастузумаба.
2. Способ лечения рака молочной железы у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств
1) соединения формулы (I")
2) летрозола.
3. Способ лечения рака молочной железы у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств
1) соединения формулы (I")
2) топотекана.
4. Способ лечения рака легких у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств
1) соединения формулы (I")
2) доцетаксела.
5. Способ лечения рака легких у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств
1) соединения формулы (I")
2) топотекана.
6. Способ лечения колоректального рака у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств
1) соединения формулы (I")
2) топотекана.
7. Способ лечения рака молочной железы у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств
1) соединения формулы (I")
2) соединения с антиэстрогенной активностью.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57733704P | 2004-06-04 | 2004-06-04 | |
| US60/577,337 | 2004-06-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006142418/14A Division RU2361589C2 (ru) | 2004-06-04 | 2005-06-03 | Способ лечения рака |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008150250A true RU2008150250A (ru) | 2010-06-27 |
Family
ID=35503649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006142418/14A RU2361589C2 (ru) | 2004-06-04 | 2005-06-03 | Способ лечения рака |
| RU2008150250/14A RU2008150250A (ru) | 2004-06-04 | 2008-12-19 | Способ лечения рака |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006142418/14A RU2361589C2 (ru) | 2004-06-04 | 2005-06-03 | Способ лечения рака |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090317383A1 (ru) |
| EP (1) | EP1765344A4 (ru) |
| JP (1) | JP2008501708A (ru) |
| KR (1) | KR20070034536A (ru) |
| CN (2) | CN101564535A (ru) |
| AU (2) | AU2005251769B2 (ru) |
| BR (1) | BRPI0511765A (ru) |
| CA (1) | CA2569139A1 (ru) |
| IL (1) | IL179323A0 (ru) |
| MA (1) | MA28901B1 (ru) |
| MX (1) | MXPA06013952A (ru) |
| NO (1) | NO20066079L (ru) |
| RU (2) | RU2361589C2 (ru) |
| WO (1) | WO2005120512A2 (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006066267A2 (en) * | 2004-12-17 | 2006-06-22 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
| WO2007143483A2 (en) * | 2006-06-01 | 2007-12-13 | Smithkline Beecham Corporation | Combination of pazopanib and lapatinib for treating cancer |
| JP2010501572A (ja) * | 2006-08-22 | 2010-01-21 | コンサート ファーマシューティカルズ インコーポレイテッド | ４−アミノキナゾリン誘導体およびその使用方法 |
| AU2007307489A1 (en) | 2006-10-06 | 2008-04-17 | Takeda Pharmaceutical Company Limited | Combination drug |
| EP2088862A4 (en) * | 2006-11-28 | 2009-12-02 | Smithkline Beecham Cork Ltd | METHOD OF TREATING CANCER |
| EP2126117A2 (en) * | 2007-01-18 | 2009-12-02 | University Of Southern California | Gene polymorphisms predictive for dual tki therapy |
| PE20091624A1 (es) | 2008-03-03 | 2009-11-19 | Takeda Pharmaceutical | Farmaco combinado a base de un inhibidor de her2 derivado de pirrolopirimidina o pirazolopirimidina |
| WO2009137714A2 (en) | 2008-05-07 | 2009-11-12 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib ditosylate and processes for preparation thereof |
| CN104523661A (zh) | 2009-02-06 | 2015-04-22 | 南加利福尼亚大学 | 含有单萜的治疗组合物 |
| US8568968B2 (en) | 2009-04-13 | 2013-10-29 | University Of Southern California | EGFR polymorphisms predict gender-related treatment |
| US20140302050A1 (en) * | 2011-11-09 | 2014-10-09 | Albert Einstein College Of Medicine Of Yeshiva University | Targeting an amphiregulin-derived cell surface neo-epitope |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
| DK0994706T3 (da) * | 1997-05-27 | 2006-03-06 | Ivax Research Inc | Præparater til oral indgivelse af taxaner og anvendelse deraf |
| GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| EE200200471A (et) * | 2000-02-28 | 2003-12-15 | Aventis Pharma S.A. | Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks |
| NZ522989A (en) * | 2000-06-30 | 2005-06-24 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
| EP1353693B1 (en) * | 2001-01-16 | 2005-03-16 | Glaxo Group Limited | Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer |
| PA8578001A1 (es) * | 2002-08-07 | 2004-05-07 | Warner Lambert Co | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas |
| EP1653986A4 (en) * | 2003-08-01 | 2007-03-14 | Smithkline Beecham Corp | TREATMENT OF P95 ERBB2 EXPRESSIVE CARCINOMA |
| US8211030B2 (en) * | 2009-03-26 | 2012-07-03 | The General Electric Company | NIBP target inflation pressure automation using derived SPO2 signals |
-
2005
- 2005-06-03 CA CA002569139A patent/CA2569139A1/en not_active Abandoned
- 2005-06-03 BR BRPI0511765-8A patent/BRPI0511765A/pt not_active IP Right Cessation
- 2005-06-03 KR KR1020067027698A patent/KR20070034536A/ko not_active Ceased
- 2005-06-03 MX MXPA06013952A patent/MXPA06013952A/es active IP Right Grant
- 2005-06-03 CN CNA2009101415491A patent/CN101564535A/zh active Pending
- 2005-06-03 CN CN200580018262XA patent/CN1984656B/zh not_active Expired - Lifetime
- 2005-06-03 WO PCT/US2005/019568 patent/WO2005120512A2/en not_active Ceased
- 2005-06-03 RU RU2006142418/14A patent/RU2361589C2/ru not_active IP Right Cessation
- 2005-06-03 AU AU2005251769A patent/AU2005251769B2/en not_active Expired
- 2005-06-03 US US11/569,878 patent/US20090317383A1/en not_active Abandoned
- 2005-06-03 EP EP05758577A patent/EP1765344A4/en not_active Withdrawn
- 2005-06-03 JP JP2007515618A patent/JP2008501708A/ja active Pending
-
2006
- 2006-11-16 IL IL179323A patent/IL179323A0/en unknown
- 2006-12-25 MA MA29554A patent/MA28901B1/fr unknown
- 2006-12-29 NO NO20066079A patent/NO20066079L/no not_active Application Discontinuation
-
2008
- 2008-10-09 AU AU2008229859A patent/AU2008229859A1/en not_active Abandoned
- 2008-12-19 RU RU2008150250/14A patent/RU2008150250A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1765344A2 (en) | 2007-03-28 |
| CA2569139A1 (en) | 2005-12-22 |
| CN1984656A (zh) | 2007-06-20 |
| AU2005251769B2 (en) | 2008-10-02 |
| MA28901B1 (fr) | 2007-10-01 |
| NO20066079L (no) | 2007-01-12 |
| BRPI0511765A (pt) | 2008-01-08 |
| WO2005120512A2 (en) | 2005-12-22 |
| RU2006142418A (ru) | 2008-07-20 |
| WO2005120512A3 (en) | 2006-04-27 |
| JP2008501708A (ja) | 2008-01-24 |
| EP1765344A4 (en) | 2009-12-02 |
| US20090317383A1 (en) | 2009-12-24 |
| CN101564535A (zh) | 2009-10-28 |
| IL179323A0 (en) | 2007-05-15 |
| KR20070034536A (ko) | 2007-03-28 |
| RU2361589C2 (ru) | 2009-07-20 |
| AU2005251769A1 (en) | 2005-12-22 |
| AU2008229859A1 (en) | 2008-10-30 |
| MXPA06013952A (es) | 2007-02-08 |
| CN1984656B (zh) | 2010-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008150250A (ru) | Способ лечения рака | |
| NO2017019I2 (no) | Enzalutamid eller et farmasøytisk akseptabelt salt derav | |
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| SG131943A1 (en) | Specific binding agents to hepatocyte growth factor | |
| RU2012140185A (ru) | Ингибирование ангиогенеза | |
| NO20091661L (no) | Anvendelse av pegylert IL-10 for a behandle kreft | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| RU2016109811A (ru) | Лечение рака комбинацией антагониста pd-1 и динациклиба | |
| ATE516819T1 (de) | Verfahren zur behandlung von b-zell-bedingtem krebs | |
| RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
| TNSN07419A1 (en) | Methods for treating drug resistant cancer | |
| JP2007510667A5 (ru) | ||
| RU2007119432A (ru) | Способ лечения рака | |
| RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака | |
| MX2007004955A (es) | Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente. | |
| RU2010141793A (ru) | Терапевтические замещенные циклопентаны | |
| ATE461713T1 (de) | Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren | |
| ATE439130T1 (de) | Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen | |
| DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
| SE0301884D0 (sv) | New use III | |
| ATE540920T1 (de) | Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie | |
| HRP20080422T3 (hr) | Satraplatin za liječenje rezistentnih ili refraktornih tumora | |
| ATE346080T1 (de) | Steroid-verbindungen mit anti-tumoraler wirkung | |
| RU2007142745A (ru) | Способ применения даларгина в комплексной терапии болезни крона | |
| TW200635609A (en) | Novel pharmaceutical composition containing at least one dolastatin 10 derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20111220 |